No apparent effect of naproxen on CSF markers of innate immune activation.

TitleNo apparent effect of naproxen on CSF markers of innate immune activation.
Publication TypeJournal Article
Year of Publication2019
AuthorsMeyer P-F, Labonte A, Rosa-Neto P, Poirier J, Breitner JCS
Corporate AuthorsPREVENT‐AD Research Group
JournalAnn Clin Transl Neurol
Volume6
Issue6
Pagination1127-1133
Date Published2019 Jun
ISSN2328-9503
Abstract

We studied 78 participants having a parental or multiple-sibling history of Alzheimer's disease (AD) in a two-year randomized placebo-controlled trial of naproxen 220 mg b.i.d. for mitigation of early AD pathogenesis. Naproxen was detected in cerebrospinal fluid at concentrations ~100 times lower than in plasma, but produced negligible change in immune markers. The repeated lack of benefit in AD prevention trials using naproxen and related drugs may reflect limited CNS permeability, lack of expected drug effects, or both. These findings suggest reconsideration of implications from results of AD prevention trials using anti-inflammatory drugs.

DOI10.1002/acn3.788
Alternate JournalAnn Clin Transl Neurol
PubMed ID31211178
PubMed Central IDPMC6562029